Evidence map›Paper›PMID 23650551›Full record

ArticlePloS one2013

Sensitization of Staphylococcus aureus to methicillin and other antibiotics in vitro and in vivo in the presence of HAMLET.

Laura R Marks, Emily A Clementi, Anders P Hakansson

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Role of serotype and virulence determinants ofFrontiers in cellular and infection microbiology · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Re-sensitizing Ampicillin and Kanamycin-ResistantFrontiers in bioengineering and biotechnology · 2020
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Laura R MarksDepartment of Microbiology and Immunology, University at Buffalo, State University of New York, Buffalo, New York, United States of America.
Emily A Clementi
Anders P Hakansson
University at Buffalo, State University of New York · US

Funding

The effect of a protein-lipid complex from human milk against pneumococcal otitisF31DC011218 · NIDCD · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI CLEMENTI, EMILY · 2010 to 2013
$68k
NIDCD NIH HHS F31 DC011218NIDCD NIH HHS F31DC011218
6 · The paper itself

Abstract

HAMLET (human alpha-lactalbumin made lethal to tumor cells) is a protein-lipid complex from human milk with both tumoricidal and bactericidal activities. HAMLET exerts a rather specific bactericidal activity against some respiratory pathogens, with highest activity against Streptococcus pneumoniae, but lacks activity against most other bacterial pathogens, including Staphylococci. Still, ion transport associated with death in S. pneumoniae is also detected to a lower degree in insensitive organisms. In this study we demonstrate that HAMLET acts as an antimicrobial adjuvant that can increase the activity of a broad spectrum of antibiotics (methicillin, vancomycin, gentamicin and erythromycin) against multi-drug resistant Staphylococcus aureus, to a degree where they become sensitive to those same antibiotics, both in antimicrobial assays against planktonic and biofilm bacteria and in an in vivo model of nasopharyngeal colonization. We show that HAMLET exerts these effects specifically by dissipating the proton gradient and inducing a sodium-dependent calcium influx that partially depolarizes the plasma membrane, the same mechanism induced during pneumococcal death. These effects results in an increased cell associated binding and/or uptake of penicillin, gentamicin and vancomycin, especially in resistant stains. Finally, HAMLET inhibits the increased resistance of methicillin seen under antibiotic pressure and the bacteria do not become resistant to the adjuvant, which is a major advantageous feature of the molecule. These results highlight HAMLET as a novel antimicrobial adjuvant with the potential to increase the clinical usefulness of antibiotics against drug resistant strains of S. aureus.

Indexed as

AnimalsAnti-Bacterial AgentsBiofilmsBoron CompoundsCalcium SignalingDrug SynergismGentamicinsLactalbuminMembrane PotentialsMethicillinMethicillin ResistanceMethicillin-Resistant Staphylococcus aureusMiceMicrobial Sensitivity TestsMicrobial ViabilityNasopharynxAnti-Bacterial AgentsBOCILLIN FLBoron CompoundsGentamicinsHAMLET complex, humanLactalbuminMethicillinOleic AcidsPenicillinsUncoupling AgentsVancomycin

Identifiers

PMID23650551
PMCPMC3641093
OpenAlexW2170502318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.